Evidence map›Paper›PMID 33547292›Full record

Trial reportNature communications2021

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.

Ziad Bakouny, David A Braun, Sachet A Shukla, Wenting Pan, Xin Gao, Yue Hou, Abdallah Flaifel, Stephen Tang, Alice Bosma-Moody, Meng Xiao He and 43 more

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 2 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 2 syntheses or guidelines pooled it, 156 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Sarcomatoid Renal Cell Carcinoma: A Clinical Review.Diagnostics (Basel, Switzerland) · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

53 authors at 11 institutions in 2 countries.

Ziad BakounyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1906-5704
David A BraunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-4543-5553
Sachet A ShuklaTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2445-3584
Wenting PanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Xin GaoDepartment of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Yue HouTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.
Abdallah FlaifelDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Stephen TangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-5492-9796
Alice Bosma-MoodyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Meng Xiao HeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Natalie VokesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-3766-5335
Jackson NymanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Wanling XieDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Amin H NassarDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-8084-9105
Sarah Abou AlaiwiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-7073-3432
Ronan FlippotDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gabrielle BouchardDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
John A SteinharterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Pier Vitale NuzzoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-5618-8079
Miriam FicialDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-2005-9267
Miriam Sant'AngeloDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Juliet FormanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jacob E BerchuckDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-7607-2428
Shaan DudaniTom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Kevin BiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jihye ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sabrina CampDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Maura Sticco-IvinsDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Laure HirschDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sylvan C BacaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Megan Wind-RotoloBristol-Myers Squibb, Princeton, NJ, USA.
Petra Ross-MacdonaldBristol-Myers Squibb, Princeton, NJ, USA.
Maxine SunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gwo-Shu Mary LeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Steven L ChangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Xiao X WeiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Bradley A McGregorDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lauren C HarshmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Giannicola GenoveseDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Leigh EllisDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0003-4739-5049
Mark PomerantzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Michelle S HirschDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Michael B AtkinsLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-3348-5054
Thai H HoDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA.ORCID 0000-0003-0023-2939
W Marston LinehanUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID 0000-0001-7983-3109
David F McDermottBeth Israel Deaconess Medical Center, Boston, MA, USA.ORCID 0000-0002-2675-5095
Daniel Y C HengTom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Srinivas R ViswanathanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1856-3023
Sabina SignorettiDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Eliezer M Van Allen *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. eliezerm_vanallen@dfci.harvard.edu.ORCID 0000-0002-0201-4444
Toni K Choueiri *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Toni_Choueiri@dfci.harvard.edu.ORCID 0000-0002-9201-3217
Dana-Farber Cancer Institute · USBrigham and Women's Hospital · USBristol-Myers Squibb (United States) · USBroad Institute · USUniversity of Calgary · CABeth Israel Deaconess Medical Center · USGeorgetown University · USMassachusetts General Hospital · USMayo Clinic in Arizona · USNational Cancer Institute · USThe University of Texas MD Anderson Cancer Center · US

Funding

Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4M
Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase GeneZIABC011038 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$29.8M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZIABC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.9M
Deciphering the interplay between H3K36 and DNA methylation in renal cancerR01CA224917 · NCI · MAYO CLINIC ROCHESTER · PI HO, THAI HUU, ROBERTSON, KEITH D · 2018 to 2022
$2.9M
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0M
Immunogenomic analytical approaches for research and clinical applicationsR50CA211482 · NCI · DANA-FARBER CANCER INST · PI SHUKLA, SACHET ASHOK · 2016 to 2020
$1.3M
Unraveling the influence of genetic subtype on spatial configurations of tissue and immune compartment composition in clear cell renal cell carcinomaF31CA250136 · NCI · HARVARD UNIVERSITY · PI NYMAN, JACKSON · 2020 to 2022
$97k
NCI NIH HHS F31 CA250136NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA224917NCI NIH HHS R01 CA227388NCI NIH HHS R50 CA211482
6 · The paper itself

Abstract

Sarcomatoid and rhabdoid (S/R) renal cell carcinoma (RCC) are highly aggressive tumors with limited molecular and clinical characterization. Emerging evidence suggests immune checkpoint inhibitors (ICI) are particularly effective for these tumors, although the biological basis for this property is largely unknown. Here, we evaluate multiple clinical trial and real-world cohorts of S/R RCC to characterize their molecular features, clinical outcomes, and immunologic characteristics. We find that S/R RCC tumors harbor distinctive molecular features that may account for their aggressive behavior, including BAP1 mutations, CDKN2A deletions, and increased expression of MYC transcriptional programs. We show that these tumors are highly responsive to ICI and that they exhibit an immune-inflamed phenotype characterized by immune activation, increased cytotoxic immune infiltration, upregulation of antigen presentation machinery genes, and PD-L1 expression. Our findings build on prior work and shed light on the molecular drivers of aggressivity and responsiveness to ICI of S/R RCC.

Indexed as

Gene Expression Regulation, NeoplasticAntineoplastic Agents, ImmunologicalB7-H1 AntigenCarcinoma, Renal CellCTLA-4 AntigenCyclin-Dependent Kinase Inhibitor p16Gene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansImmune Checkpoint InhibitorsImmune Checkpoint ProteinsKidney NeoplasmsMutationProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-mycRetrospective StudiesAntineoplastic Agents, ImmunologicalB7-H1 AntigenBAP1 protein, humanCD274 protein, humanCDKN2A protein, humanCTLA-4 AntigenCTLA4 protein, humanCyclin-Dependent Kinase Inhibitor p16Immune Checkpoint InhibitorsImmune Checkpoint ProteinsMYC protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-mycTumor Suppressor ProteinsUbiquitin Thiolesterase

Identifiers

PMID33547292
PMCPMC7865061
OpenAlexW3128607514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.